Journal of Clinical Ligand Assay

Tumor Markers: A New Era
pp. 5-5(1)
Authors: Fritsche H. A.; Witek D. L.

The NCI EDRN Approach to Molecular Targets for Earlier Cancer Detection and Identification of Risk
pp. 6-10(5)
Authors: Verma M.; Negm R.; Srivastava S.

Tumor Markers and Pattern Recognition Analysis: A New Diagnostic Tool for Cancer
pp. 11-15(5)
Author: Fritsche H. A.

Estrogen Receptor-: Role in Breast Cancer
pp. 16-19(4)
Authors: Cullen R.; Maguire T. M.; McDermott E. W.; Hill A. D.K.; O'Higgins N. J.; Duffy M. J.

A Cancer-Specific Form of Proliferating Cell Nuclear Antigen (csPCNA) Is Present in Malignant Human Breast Cells and Tissues
pp. 20-32(13)
Authors: Malkas L.H.; Bechtel P.E.; Sekowski J.W.; Schnaper L.; Lankford C.R.-V.; Hoelz D.J.; Tomic D.; Hickey R.J.

The RAK Alpha Gene in Cancer Diagnosis
pp. 33-39(7)
Author: Rakowicz-Szulczynska E. M.

Cytokeratins—Clinical Utility in Breast Cancer
pp. 40-42(3)
Authors: Barak V.; Nisman B.; Hubert A.; Lyass O.; Peretz T.

The Urokinase Protease System as a Target for Breast Cancer Prognosis and Therapy: Technical Considerations
pp. 43-52(10)
Authors: Schmitt M.; Lienert S.; Prechtel D.; Sedlaczek E.; Welk A.; Reuning U.; Magdolen V.; Jänicke F.; Sweep C.G.J.; Harbeck N.

Measurement of Soluble Urokinase Plasminogen Activator Receptor in Serum
pp. 53-56(4)
Authors: Riisbro R.; Piironen T.; Brünner N.; Larsen B.; Nielsen H.J.; Stephens R. W.; Høyer-Hansen G.

EGF Receptor/ErbB Isoforms as Serum Biomarkers in Breast and Ovarian Cancer
pp. 57-60(4)
Authors: Maihle N. J.; Lafky J. M.; Baron A. T.; Boardman C. H.; Greenwood T. M.; Christensen T. A.; Reiter J. L.; Cora E. M.; Lee H.; Suman V. J.; Fishman D. A.; Perez E. A.; Podratz K. C.

Prostate Tumor Markers: An Overview
pp. 61-66(6)
Authors: Babaian R.J.; Okihara K.

Discrimination of Prostate Cancer from Benign Disease by Selective Measurements of Serum Subfractions of Free PSA That Are Not Internally Cleaved at Lys145-Lys146
pp. 67-69(3)
Authors: Nurmikko P.; Steuber T.; Haese A.; Pettersson K.; Hammerer P.; Huland H.; Lilja H.

BPSA in Benign Prostate Disease and ProPSA in Malignant Disease Are Complementary Forms of Prostate Specific Antigen in the Serum
pp. 70-73(4)
Authors: Mikolajczyk S. D.; Rittenhouse H. G.

Fibronectin and Prostate Cancer
pp. 74-79(6)
Authors: Chakrabarty S.; Fritsche H. A.

Markers for Bladder Cancer
pp. 80-82(3)
Author: Grossman H.B.

Utilization of a Urine-based Assay for BLCA-4 in the Detection of Bladder Cancer
pp. 83-86(4)
Authors: Davido H.T.; Getzenberg R. H.

Characterization of Monoclonal Antibodies to Tissue Inhibitor of Metalloproteinases-1
pp. 87-90(4)
Authors: Holten-Andersen M.N.; Brünner N.; Maimonis P.; Jensen V.; Murphy G.; Piironen T.

A Novel Method for the Quantification of the Galactose Oxidase-Schiff's Reaction and Its Use in Cancer Detection
pp. 91-94(4)
Author: Evelegh M. J.

Aberrant Promoter Methylation in Sputum and Serum for Lung Cancer Detection
pp. 95-99(5)
Authors: Belinsky S. A.; Divine K. K.; Esteller M.; Baylin S. B.; Herman J. G.; Palmisano W. A.

Heterogeneous Nuclear Ribonucleoprotein A2/B1 (hnRNP A2/B1) as a Marker of Preinvasive Lung Cancer
pp. 100-103(4)
Authors: Martínez A.; Mulshine J. L.

A Sample Preparation and Analysis System for Identification of Circulating Tumor Cells
pp. 104-110(7)
Authors: Kagan M.; Howard D.; Bendele T.; Mayes J.; Silvia J.; Repollet M.; Doyle J.; Allard J.; Tu N.; Bui T.; Russell T.; Rao C.; Hermann M.; Rutner H.; Terstappen L.W.M.M.

Tumor Markers: A New Era— The Rapporteur's Summary
pp. 111-114(4)
Author: Schwartz M. K.

Additional Abstracts from the Second Santa Barbara Conference on Tumor Markers
pp. 116-124(9)